Antibody-Drug Conjugates in the Treatment of Esophageal Cancer.
Esophageal cancer remains one of the most lethal malignancies worldwide, with particularly poor outcomes following disease progression after first-line chemoimmunotherapy. Antibody-drug conjugates (ADCs) have emerged as a transformative therapeutic class that combines the targeting precision of monoclonal antibodies with potent cytotoxic payloads, en.
Esophageal cancer remains one of the most lethal malignancies worldwide, with particularly poor outcomes following disease progression after first-line chemoimmunotherapy. Antibody-drug conjugates (ADCs) have emerged as a transformative therapeutic class that combines the targeting precision of monoclonal antibodies with potent cytotoxic payloads, en.
What the study was
- Study design
- Clinical Trial Phase III
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Current treatment options in oncology
Why it surfaced
HIGH priority (score 10/10); study design: Clinical Trial Phase III; topic: Novel therapeutics: immunotherapy, CAR-T, targeted therapy; flag: PROMISING_PRELIMINARY
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.